No vaccine-related serious
adverse events were reported during the studies. Neutralizing antibodies against dengue viruses 1–4 waned during the
1–3 years before boosting, which elicited a short-lived booster response but did not provide a long-lived, multivalent
antibody response in most subjects. Overall, this candidate vaccine did not elicit a durable humoral immune response